Cell Response Ltd

Cell Response Ltd

Biotechnology Research

We're dedicated to defeating cancer drug resistance.

About us

Over 90% of cancer patient mortality is due to drug resistance and most clinical trials fail due to drug resistance. Our proprietary synthetic lethality screening platform, Resistome™, rapidly identifies drug-specific resistance mechanisms and evaluates drug combinations which overcome drug-specific resistance to extend life for patients, as well as identifying refined biomarker strategies to improve the stratification of patients for treatment.

Website
www.cellresponsetx.com
Industry
Biotechnology Research
Company size
2-10 employees
Type
Privately Held
Specialties
oncology drug resistance

Employees at Cell Response Ltd

Updates

Similar pages